Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|September 30, 2015
Highlights at CPhI Worldwide 2015
The 26th annual CPhI Worldwide exhibition and co-located events-ICSE, InnoPack, and P-Mec-bring together pharmaceutical industry professionals from around the world to view equipment and services exhibits, attend educational conferences, network with industry peers, and conduct business.
Advertisement
Pharma industry experts from around the world will head to Madrid, Spain this October for exhibitions, conferences, networking, and business meetings at
Pre-Connect Congress
Now in its 7th year, the
Pharma Forum
New this year at CPhI Worldwide 2015 is the Pharma Forum, a dedicated content village and central hub for thought leadership from industry players and media partners. It offers visitors access to the latest innovative products and services in the Innovation Gallery as well as materials from the Pharma Insight Briefings
Pharma Insight Briefings
Pharma Awards
The
Women’s Networking Breakfast
Building on a successful inaugural event in 2014, the Women’s Networking Breakfast provides an opportunity for female executives from global pharmaceutical companies to meet, develop new business contacts, and learn how to advance in the pharma industry. The breakfast is scheduled for Wednesday, 14 October, 08:30-11:00, at the Novotel Campo de las Naciones, Madrid. For details, visit:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5